Alnylam Pharmaceuticals: H.C. Wainwright cuts target price to $250 from $455
ALNY•H.C. Wainwright cut its target price for Alnylam Pharmaceuticals to $250 from $455.
Related News

ITT names Blaine Browers CFO, effective Jan. 1, 2027
ITT•

EON Resources delays third-quarter 2026 financial report
EONR•

Zone Frontier delays quarterly filing over warrant accounting review
ZONE•

Game Your Game delays quarterly filing to review reseller transaction accounting
GYGY•

Liminatus Pharma delays quarterly report as financial statements remain incomplete
LIMN•